ST-920 isaralgagene civaparvovec Updated Oct 30
Watch for completion of the rolling BLA submission to the FDA in Q4 2026 (by Dec 31). If submitted on time, the FDA will set a PDUFA date, likely in H2 2027, which would be the next major binary catalyst. Any delay in the BLA submission would be a negative signal. Also monitor the WORLD Symposium in February 2027 for updated clinical data.
- ST-920 is a one-time gene therapy that could replace lifelong biweekly enzyme replacement infusions for Fabry disease, a clear value proposition for patients and payers.
- The Phase 1/2 STAAR study showed a positive mean annualized eGFR slope of +1.965 at 52 weeks, indicating renal function improvement, and the FDA agreed this can serve as the primary basis for accelerated approval.
- The therapy requires no preconditioning (no chemotherapy), simplifying administration versus some other gene therapies.
- The BLA submission is based on a single-arm Phase 1/2 study (STAAR) with 32-36 patients, not a randomized controlled trial, which raises regulatory risk for full approval.
- The 95% confidence interval for the eGFR slope (-0.153 to 4.083) crosses zero, meaning the result was not statistically significant at conventional levels.
- Competing gene therapies from 4D Molecular Therapeutics (4D-310) and Freeline are also in development, and established ERT products (Fabrazyme, Replagal) and oral chaperone Galafold already serve the market.